Gene D. Morse, PharmD, BCPS, FCCP

Gene D. Morse, PharmD, BCPS, FCCP

University at Buffalo

Professor, Pharmacy Practice, Medicine and Pediatrics
Associate Director
NYS Center of Excellence in Bioinformatics and Life Sciences
University at Buffalo
Buffalo, New York

Institutional Website


Committees and Organizations

  • 2012 – present    Member, AACP Volwiler Research Achievement Award Selection Committee
  • 2012 – present    Member, New York State Department of Health, AIDS Institute, Pharmacy Advisory Committee
  • 2010 – present    Member, American Society of Nanomedicine
  • 2010 – present    ACCP Abstract Reviewer – Original Research, Clinical Pharmacy Forum, and Student/Resident Research-in-Progress
  • 2010 – present    Member, Steering Committee of the NY HIV Research Centers Consortium
  • 2010 – present    Co-Director, UNYTE Translational Research Network – University of Rochester CTSA
  • 2009 – present    Consultant, FDA Antiretroviral Drugs Advisory Committee (AVDAC)

Honors and Awards

  • 2013 ACCP Research Institute Trustee Nominee (Spring 2014 Ballot)
  • 2012 Amer Assoc of Colleges of Pharmacy, Volwiler Research Achievement Award
  • 2010 UB Council on International Studies and Programs Award for Outstanding Contributions to International Education


  • University of Albany, SUNY, BS, Biology (1976)
  • University of Buffalo, SUNY, BS, Pharmacy (1980)
  • Moses Cone Memorial Hospital, Greensboro, NY, Resident, Hospital Pharmacy (1981)
  • University of Buffalo, SUNY, PharmD (1983)
  • University of Buffalo, SUNY, Fellow, Clinical Pharmacokinetics (1984)

Selected Publications

  1. Mudzviti T, Sibanda M, Gavi S, Maponga CC, Morse GD. Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program. J Infect Dev Ctries. 2012 Nov 26;6(11):806-8. doi: 10.3855/jidc.1908. PMCID: PMC3535441
  2. Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW. Genome-Wide Association Study of Plasma Efavirenz Pharmacokinetics in AIDS Clinical Trials Group Protocols Implicates Several CYP2B6 Variants. Pharmacogenet and Genomics. 2012 Dec;22(12):858-867.. [Epub ahead of print] PMID: 23080225
  3. Oramasionwu CU, Koeller JM, Lawson KA, Brown CM, Morse GD, Frei CR. The State of Disparities in Opportunistic Infection Prophylaxis for Blacks with HIV/AIDS. Med Care. 2012 Nov. 50(11):920-7. PMCID: PMC3470654
  4. Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, Fischl MA, Collier AC, Haas DW. Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-boosted Atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis. 2013 Feb;207(3):420-425. [Epub 2012 Nov 12] PMCID: PMC3537445
  5. DiFrancesco R, Maduke G, Patel R, Taylor CR, Morse GD. Antiretroviral bioanalysis methods of tissues and body biofluids. Bioanalysis. 2013 Feb;5(3):351-68. doi: 10.4155/bio.12.319. PMID: 23394701
  6. Zhang X, Tierney C, Albrecht M, Demeter LM, Morse GD, DiFrancesco R, Dykes C, Jiang H, Haas DW. Discordant Associations between SLCO1B1 21TàC and Plasma Levels of Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study A5146.Ther Drug Monit.2013 Apr;35(2):209-16. doi: 10.1097/FTD.0b013e318280d0ad. PMCID: PMC3603284
  7. DiFrancesco R, Tooley K, Rosenkranz SL, Siminski S, Taylor CR, Pande P, Morse GD. Clinical Pharmacology Quality Assurance for HIV and Related Infectious Diseases Research. Clinical Pharmacology & Therapeutics. 2013 Jun;93(6):479-82. PMID: 23588323
  8. DiFrancesco R, Rosenkranz SL, Taylor CR, Pande PG, Siminski SM, Jenny RW, Morse GD. Clinical Pharmacology Quality Assurance (CPQA) Program: Longitudinal Analysis of Antiretroviral (ARV) Proficiency Testing for International Laboratories. Ther Drug Monit. Accepted.
  9. McCance-Katz EF, Gruber V, Beatty G, Lum PJ, Ma Q, DiFrancesco R, Hochreiter J, Wallace PK, Morse GD. Interaction of Disulfiram with Efavirenz, Ritonavir or Atazanavir. Am J Addict. Accepted.
  10. Mikula J, Sawyer JR, Ma Q, Sulaiman AS, Hsiao CB, Morse GD. Comparative effectiveness of darunavir 1,200 mg daily and approved dosing strategies for protease inhibitor-experienced patients. AIDS Res Treat. 2013 June. Vol. 2013, Article ID 687176, 4 pages. doi:10.1155/2013/687176